https://nice-chaplygin.213-158-90-7.plesk.page/fiercebiotechinterview/ 2022-11-09T10:32:21+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/12/ALS-MND-2024_Rougemont_ATXN2_BIO-16_FINAL.pdf#new_tab 2024-12-10T11:07:58+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/12/ALS-MND-2024_Coan_ATXN2-KD_TST-01_FINAL.pdf#new_tab 2024-12-10T11:08:02+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/12/ALS-MND-2024_Reilly_SOD1_TST-24_FINAL.pdf#new_tab 2024-12-10T11:08:21+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/10/ESGCT-2024_vMiX-Platform-Development_DIGITAL_v2_PRINT.pdf#new_tab 2024-12-10T11:08:29+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/10/ESGCT-2024_SOD1-Targeting_PRINT.pdf#new_tab 2024-12-10T11:08:36+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/10/ESGCT-2024_In-Vitro-Potency-Assay_PRINT.pdf#new_tab 2024-12-10T11:08:44+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/10/ESGCT-2024_Triplex-RT-ddPCR-Method_PRINT.pdf#new_tab 2024-12-10T11:08:52+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/10/ESGCT-2024_Tailored-miRNA-Gene-Therapy_PRINT.pdf#new_tab 2024-12-10T11:09:17+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/10/ESGCT-2024_AVB-205-ATXN-2-Knockdown_PRINT.pdf#new_tab 2024-12-10T11:09:24+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/10/ESGCT-2024_HPLC-Based-Methods_PRINT.pdf#new_tab 2024-12-10T11:09:31+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/09/ISFTD-2024_AVB-101_DIGITAL-1.pdf#new_tab 2024-12-10T11:09:36+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/09/ISFTD-2024_FHD_DIGITAL_FINAL_04Sep2024-1.pdf#new_tab 2024-12-10T11:09:45+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/09/ISFTD-2024_AVB-Trial-Design_DIGITAL_FINAL_04Sep2024-1.pdf#new_tab 2024-12-10T11:09:52+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/07/AAIC-2024_AVB-101_FINAL_DIGITAL.pdf#new_tab 2024-12-10T11:09:58+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/05/ASGCT-2024_First-Applications_Approval.pdf#new_tab 2024-12-10T11:10:04+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/05/ASGCT-2024_vMiX_Plug-and-Play.pdf#new_tab 2024-12-10T11:10:09+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2023/10/ESGCT2023.pdf#new_tab 2024-12-10T11:10:17+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2023/10/ISFTD2022.pdf#new_tab 2024-12-12T11:15:36+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2023/10/ESGCT-2022.pdf#new_tab 2024-12-12T11:16:51+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2025/05/ASGCT2025.pdf#new_tab 2025-05-27T10:14:10+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-announces-aspire-ftd-phase-1-2-clinical-trial-in-the-uk/ 2025-07-25T16:04:26+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-announces-completion-of-second-cohort-in-phase-1-2-aspire-ftd-clinical-trial/ 2025-07-25T16:04:36+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/astellas-and-aviadobio-announce-exclusive-option-and-license-agreement-for-gene-therapy-avb-101-targeting-frontotemporal-dementia-and-other-indications/ 2025-07-25T16:05:24+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/07/AviadoBio-video-icon-square-2.png https://nice-chaplygin.213-158-90-7.plesk.page/aspire-ftd-phase-1-2-clinical-trial-opens-in-the-u-s-at-the-ohio-state-university-wexner-medical-center/ 2025-07-25T16:05:28+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2024/07/AviadoBio-video-icon-square-2.png https://nice-chaplygin.213-158-90-7.plesk.page/first-patient-treated-in-aspire-ftd-clinical-trial/ 2025-07-25T16:07:10+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-appoints-john-isaac-as-chief-scientific-officer/ 2025-07-25T16:07:16+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-announces-fda-ind-clearance-and-fast-track-designation-for-avb-101-for-the-treatment-of-frontotemporal-dementia-with-progranulin-grn-mutations/ 2025-07-25T16:07:20+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-announces-presentation-of-promising-preclinical-safety-and-biodistribution-data-of-its-gene-therapy-candidate-avb-101-for-ftd-grn-at-the-annual-european-society-of-gene-and-cell-therapy-con/ 2025-07-25T16:07:25+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-announces-initiation-of-phase-1-2-clinical-trial-aspire-ftd/ 2025-07-25T16:07:29+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-signs-exclusive-license-agreement-with-neurgain-technologies/ 2025-07-25T16:07:34+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-announces-appointment-of-jeff-goater-as-chair-of-the-board-of-directors/ 2025-07-25T16:07:38+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-appoints-graeme-fielder-as-chief-operating-officer-and-alex-bloom-as-chief-technical-officer/ 2025-07-25T16:07:42+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-selected-by-fierce-biotech-as-a-fierce-15-2022-winner/ 2025-07-25T16:07:46+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/appoints-dr-david-cooper-as-chief-medical-officer/ 2025-07-25T16:07:51+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-presents-preclinical-data-at-asgct-2022/ 2025-07-25T16:07:56+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-announces-formation-of-scientific-advisory-board/ 2025-07-25T16:08:01+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-to-present-pre-clinical-data-on-its-gene-therapy-candidate-for-frontotemporal-dementia-at-asgct-2022/ 2025-07-25T16:08:05+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobios-gene-therapy-candidate-receives-orphan-designation/ 2025-07-25T16:08:09+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-raises-80-million-in-series-a-financing-to-advance-neurodegenerative-gene-therapy-platform/ 2025-07-25T16:08:13+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2025/07/AAIC-2025-OM1_FTD-RWD-Characterisation_FINAL_DIGITAL.pdf#new_tab 2025-07-31T08:00:05+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2025/07/AAIC-2025-AVB-101-Clinical-Study-Update_FINAL_DIGITAL.pdf#new_tab 2025-07-31T08:01:06+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2025/10/ESGCT-Poster-2025_V1.0_RL_PRINT_FINAL.pdf#new_tab 2025-10-07T13:00:09+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2025/10/ESGCT_2025_Poster_AA_P0177_FINAL_QRCode.pdf#new_tab 2025-10-07T13:00:22+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2025/10/ESGCT-Poster-LSB-final.pdf#new_tab 2025-10-07T13:00:31+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/wp-content/uploads/2025/10/ESGCT-2025-poster-ZW-ED-FINAL.pdf#new_tab 2025-10-07T13:00:52+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-and-ugenex-therapeutics-announce-exclusive-option-license-agreement/ 2025-10-09T08:00:12+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/a-community-update-from-aviadobio-on-the-aspire-ftd-clinical-trial/ 2026-04-02T15:07:23+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-advances-avb-101-gene-therapy-program-and-initiates-fourth-dose-escalation-cohort-of-phase-1-2-aspire-ftd-trial/ 2026-04-27T21:00:42+00:00 https://nice-chaplygin.213-158-90-7.plesk.page/aviadobio-announces-agreement-with-apertura-gene-therapy-to-license-tfr1-capx-a-next-generation-blood-brain-barrier-crossing-capsid/ 2026-04-27T21:01:31+00:00